Rucaparib (Rubraca® ): interim data from Study CO-338-043 (ARIEL4) show a decrease in overall survival compared to standard of care
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Active substance |
rucaparib camsylate
|
| Therapeutic area (MeSH) |
Ovarian Neoplasms
|
| Procedure number |
EMEA/H/A-20/1518/C/4272/0033
|
| Regulatory outcome |
Variation
|
| DHPC type |
Referral - Article 20 procedure
|
| Referral name |
Rubraca
|
| Human ATC code |
L01XX
|
| Dissemination date |
05/05/2022
|